A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Study Overview

The purpose of this study is to test the safety, tolerability, and effectiveness (how well these drugs work together) of the study drug (NKTR-214) given together with Opdivo?.

Study Description

The purpose of this study is to study the safety, tolerability, and effectiveness of the study drug (NKTR-214) given together with Opdivo.

Additional Information

Participants will be compensated for their participation.

IRB Number: 1705311414 (NKTR16-214-02)
Research Study Identifier: TX7957
Principal Investigator: Roberto Pili, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Open

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176

A Phase 1/2 Open-label Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214 Nivolumab and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Study Overview

Study Description

Additional Information

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

Volunteer Registry